SWM
DFTX

Spire Wealth Management’s Definium Therapeutics DFTX Stock Holding History

Spire Wealth Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,040
Closed -$7.24K – 2542
2024
Q4 		$7.24K Buy
+1,040
New +$7.16K ﹤0.01% 1939
2022
Q3 		– Sell
-123
Closed -$1K – 2452
2022
Q2 		$1K Buy
+123
New +$1.56K ﹤0.01% 2543

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Spire Wealth Management's DFTX Position: Q1 2025 in Review

Spire Wealth Management sold out of Definium Therapeutics (DFTX) in Q1 2025, closing a stake of 1,040 shares — an estimated $7.24K sold.

Spire Wealth Management first reported a position in DFTX in Q2 2022 and held it in 2 quarters. The position peaked at $7.24K in Q4 2024. 190 funds tracked by Wall St. Rank hold DFTX as of Q1 2025.

  • Spire Wealth Management reported no remaining Definium Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Spire Wealth Management sold 1,040 Definium Therapeutics shares in Q1 2025, an estimated $7.24K.
  • Spire Wealth Management first reported a position in Definium Therapeutics in Q2 2022 and held it in 2 quarters.
  • Spire Wealth Management's Definium Therapeutics position peaked at $7.24K in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2025.

Based on Spire Wealth Management's 13F filing for Q1 2025, filed 23 Apr 2025.